MassBiologicsDecember 18, 2025

FDA 483 - MassBiologics - December 18, 2025

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore MassBiologics

Record Details

An FDA inspection of MassBiologics, a Gene Therapy Testing Lab in Boston, revealed a significant deficiency regarding written procedures. The firm failed to establish and follow written procedures for annual evaluations, including reviews of complaints, recalls, and investigations for each drug product. Specifically, quality indicator reports for Kebilidi manufacturing lacked proper documentation and visual representation of drug product batch release data trends.

Company: MassBiologics
Inspection Date: December 18, 2025
Product Type: Biologics
Office: New England District Office
Person: Scott T. Ballard

Open in Dashboard

ID · 32cddc50-58d8-43da-866b-326888199b33